Upon retrospective analysis of two clinical trials assessing different antiangiogenic drugs, we found that high-AIMP2 subgroups had improved response to therapies in GBM [REGOMA: HR, 4.75 (1.96–11.5), P < 0.001; BELOB: HR, 2.3 (1.17–4.49), P = 0.015]. Here, AIMP2 is linked to glioblastoma.